Linking Diet, Inflammation, Gut Microbiota, and Sarcopenia: A Cross-Sectional Study

NCT07211321 | Recruiting

• 2 other identifiers: IRB23070101No. 23JRRA1064
• Study Type: observational
• Target: 1,220
• Locations: 1 country
• Sites: 1

Brief Summary

Based on the analysis of dietary characteristics, gut microbiota diversity, and composition, this study investigates the relationships between the dietary inflammatory potential, gut microbiota, and sarcopenia. Furthermore, it explores the mediating role of gut microbiota in the association between the dietary inflammatory index and the risk of sarcopenia. The findings are expected to provide insights into the mechanisms through which dietary inflammation influences the development and progression of sarcopenia, and to offer a basis for dietary and nutritional interventions aimed at preventing or managing this condition.

Conditions

Sarcopenia

Outcome Measures

Primary Outcomes (3)

• The prevalence of sarcopenia

  The diagnosis of sarcopenia is confirmed according to the AWGS 2019 criteria, which requires the assessment of muscle strength, physical performance, and muscle mass.

  Through study completion, an average of 1 year

• Change in absolute abundance of Faecalibacterium prausnitzii

  16S rRNA absolute quantification was used to detect the microbial composition of the fecal samples.

  Through study completion, an average of 1 year

• Dietary Characteristics

  Dietary data were collected using a food frequency questionnaire (FFQ) to analyze dietary patterns and nutrient intake.

  Through study completion, an average of 1 year

Study Arms (1)

sarcopenia group and control group

Other: No Intervention: Observational Cohort

Interventions

No Intervention: Observational Cohort OTHER

No Intervention

sarcopenia group and control group

Eligibility Criteria

• Age: 60 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

This community-based cross-sectional study enrolled permanent residents aged 60 years or older who had been living in the community for more than 5 years.

You may qualify if:

• Permanent residents of the community aged 60 years or older.
• Continuous residence duration in the community for more than 5 years.

You may not qualify if:

• Taking medications known to affect muscle function (e.g., corticosteroids, protein supplements, muscle enhancers).
• Requiring walking assistance or having severe cognitive impairment that would preclude successful completion of assessments including bioelectrical impedance analysis (BIA), gait speed measurement, and handgrip strength testing.
• Presence of a cardiac pacemaker, which contraindicates BIA measurement.
• Diagnosis of one or more chronic diseases that significantly limit dietary intake.

Sponsors & Collaborators

• Jianhua Ma: lead

Study Sites (1)

Lanzhou university

Lanzhou, Gansu, 730000, China

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Faecal and whole blood samples

MeSH Terms

Conditions

Sarcopenia

Condition Hierarchy (Ancestors)

Muscular Atrophy; Neuromuscular Manifestations; Neurologic Manifestations; Nervous System Diseases; Atrophy; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms; Signs and Symptoms

Central Study Contacts

Jianhua Ma Doctor of Medicine

CONTACT

0086 18993157029; majianhua@lzu.edu.cn

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Lecturer

Study Record Dates

• First Submitted: September 17, 2025
• First Posted: October 7, 2025
• Study Start: April 16, 2024
• Primary Completion: December 31, 2025
• Study Completion: December 31, 2025
• Last Updated: October 7, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)